Basal C-peptide Level as a Surrogate Marker of Subclinical Atherosclerosis in Type 2 Diabetic Patients

Background Recent studies have revealed that C-peptide induces smooth muscle cell proliferation and causes human atherosclerotic lesions in diabetic patients. The present study was designed to examine whether the basal C-peptide levels correlate with cardiovascular risk in type 2 diabetes mellitus (T2DM) patients. Methods Data was obtained from 467 patients with T2DM from two institutions who were followed for four years. The medical findings of all patients were reviewed, and patients with creatinine >1.4 mg/dL, any inflammation or infection, hepatitis, or type 1 DM were excluded. The relationships between basal C-peptide and other clinical values were statistically analyzed. Results A simple correlation was found between basal C-peptide and components of metabolic syndrome (MS). Statistically basal C-peptide levels were significantly higher than the three different MS criteria used in the present study, the Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program's (NCEP's), World Health Organization (WHO), and the International Diabetes Federation (IDF) criteria (NCEP-ATP III, P=0.001; IDF, P<0.001; WHO, P=0.029). The multiple regression analysis between intima-media thickness (IMT) and clinical values showed that basal C-peptide significantly correlated with IMT (P=0.043), while the analysis between the 10-year coronary heart disease risk by the United Kingdom Prospective Diabetes Study risk engine and clinical values showed that basal C-peptide did not correlate with IMT (P=0.226). Conclusion Basal C-peptide is related to cardiovascular predictors (IMT) of T2DM, suggesting that basal C-peptide does provide a further indication of cardiovascular disease.

[1]  V. Raghavan.  Insulin resistance and atherosclerosis. , 2012, Heart failure clinics.

[2]  Michael E. Miller,et al.  Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes , 2011 .

[3]  L. Nordquist,et al.  Proinsulin C-peptide: Friend or foe in the development of diabetes-associated complications? , 2008, Vascular health and risk management.

[4]  C. Ahn,et al.  Association of Abdominal Obesity with Atherosclerosis in Type 2 Diabetes Mellitus (T2DM) in Korea , 2008, Journal of Korean medical science.

[5]  R. Klein,et al.  Relationship of Glycemic Control, Exogenous Insulin, and C-Peptide Levels to Ischemic Heart Disease Mortality Over a 16-Year Period in People With Older-Onset Diabetes , 2008, Diabetes Care.

[6]  D. Bruemmer.  C-Peptide in insulin resistance and vascular complications: teaching an old dog new tricks. , 2006, Circulation research.

[7]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[8]  B. Draznin,et al.  Molecular mechanisms of insulin resistance that impact cardiovascular biology. , 2004, Diabetes.

[9]  N. Day,et al.  Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk , 2004, Annals of Internal Medicine.

[10]  P. Ridker,et al.  Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. , 2004, Circulation.

[11]  P. Libby,et al.  C-Peptide Colocalizes with Macrophages in Early Arteriosclerotic Lesions of Diabetic Subjects and Induces Monocyte Chemotaxis In Vitro , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[12]  J. Johansson,et al.  Molecular effects of proinsulin C-peptide. , 2002, Biochemical and biophysical research communications.

[13]  Ĺ. Ozdín,et al.  Role of fasting serum C-peptide as a predictor of cardiovascular risk associated with the metabolic X-syndrome. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[14]  E. Topol,et al.  Neointimal Hyperplasia After Arterial Injury Is Increased in a Rat Model of Non–Insulin-Dependent Diabetes Mellitus , 2001, Circulation.

[15]  M. Denke,et al.  Defining and treating the metabolic syndrome: A primer from the Adult Treatment Panel III , 2001, Current treatment options in cardiovascular medicine.

[16]  J. Schlessinger.  New Roles for Src Kinases in Control of Cell Survival and Angiogenesis , 2000, Cell.

[17]  G Kratz,et al.  Specific binding of proinsulin C-peptide to human cell membranes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[19]  E. Lonn.  Carotid artery intima-media thickness--a new noninvasive gold standard for assessing the anatomic extent of atherosclerosis and cardiovascular risk? , 1999, Clinical and investigative medicine. Medecine clinique et experimentale.

[20]  C. H. Chen,et al.  Correlation of fasting serum C-peptide and insulin with markers of metabolic syndrome-X in a homogenous Chinese population with normal glucose tolerance. , 1999, International journal of cardiology.

[21]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[22]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[23]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[24]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[25]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[26]  R. Bergman,et al.  Insulin Sensitivity and Atherosclerosis , 1996 .

[27]  C. Hales,et al.  How to measure plasma insulin. , 1994, Diabetes/metabolism reviews.

[28]  A. Folsom,et al.  Relation of Carotid Artery Wall Thickness to Diabetes Mellitus, Fasting Glucose and Insulin, Body Size, and Physical Activity , 1994, Stroke.

[29]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[30]  P. Savage,et al.  Association of fasting insulin with blood pressure and lipids in young adults. The CARDIA study. , 1990, Arteriosclerosis.

[31]  S. O’Rahilly,et al.  Haemolysis affects insulin but not C-peptide immunoassay , 1987, Diabetologia.

[32]  A. Kitabchi.  Proinsulin and C-peptide: a review. , 1977, Metabolism: clinical and experimental.

[33]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[34]  R. Bergman,et al.  Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. , 1996, Circulation.

[35]  L. Kuller,et al.  Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial. , 1994, Annals of epidemiology.

[36]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.